Immunocore Hldgs第四季度每股收益$(0.47) 低于预期$(0.24),销售额$84.05M 超过预期$83.55M

财报速递
26 Feb
Immunocore Hldgs (NASDAQ:IMCR)报告季度每股亏损$(0.47),低于分析师一致预期的$(0.24),差距为95.83%。与去年同期每股亏损$(0.40)相比,这一数据减少了17.5%。公司报告季度销售额为$84.05M,高于分析师一致预期的$83.55M,增幅为0.60%。与去年同期销售额$70.16M相比,这一数据增长了19.80%。

以上内容来自Benzinga Earnings专栏,原文如下:

Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.24) by 95.83 percent. This is a 17.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $84.05 million which beat the analyst consensus estimate of $83.55 million by 0.60 percent. This is a 19.80 percent increase over sales of $70.16 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10